
    
      The current study is designed as a prospective placebo-controlled trial to investigate the
      safety and efficacy of a lower dose of dalfampridine extended release tablets (5 mg twice
      daily) compared to the approved commercial dose of 10 mg twice daily in improving walking in
      MS patients during a four-week period of treatment.
    
  